These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24953388)

  • 1. Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure.
    Tziomalos K; Karagiannis A; Athyros VG
    Curr Pharm Des; 2014; 20(40):6306-13. PubMed ID: 24953388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.
    Okopień B; Krysiak R; Herman ZS
    J Clin Endocrinol Metab; 2006 May; 91(5):1770-8. PubMed ID: 16492702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond lipid lowering: the anti-hypertensive role of statins.
    Chopra V; Choksi PU; Cavusoglu E
    Cardiovasc Drugs Ther; 2007 Jun; 21(3):161-9. PubMed ID: 17468937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of lipid-regulating therapy on haemostatic parameters.
    Milionis HJ; Elisaf MS; Mikhailidis DP
    Curr Pharm Des; 2003; 9(29):2425-43. PubMed ID: 14529557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid lowering agents and the endothelium: an update after 4 years.
    Tziomalos K; Athyros VG; Karagiannis A; Mikhailidis DP
    Curr Vasc Pharmacol; 2012 Jan; 10(1):33-41. PubMed ID: 22112353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells.
    Suades R; Padró T; Alonso R; Mata P; Badimon L
    Thromb Haemost; 2013 Aug; 110(2):366-77. PubMed ID: 23740299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive LDL-cholesterol lowering therapy and neurocognitive function.
    Banach M; Rizzo M; Nikolic D; Howard G; Howard V; Mikhailidis D
    Pharmacol Ther; 2017 Feb; 170():181-191. PubMed ID: 27865998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Statins: therapeutic cascade of their effects].
    Aronov DM
    Kardiologiia; 2004; 44(10):85-94. PubMed ID: 15477799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CEPHEUS Pan-Asian survey: high low-density lipoprotein cholesterol goal attainment rate among hypercholesterolaemic patients undergoing lipid-lowering treatment in a Hong Kong regional centre.
    Chan RH; Chan PH; Chan KK; Lam SC; Hai JJ; Wong MK; Tam FC; Lam L; Chan CW; Lam YM; Siu DC; Tse HF; Lee SW
    Hong Kong Med J; 2012 Oct; 18(5):395-406. PubMed ID: 23018067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).
    Zhao S; Wang Y; Mu Y; Yu B; Ye P; Yan X; Li Z; Wei Y; Ambegaonakr BM; Hu D;
    Atherosclerosis; 2014 Aug; 235(2):463-9. PubMed ID: 24950001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].
    Mamedov MN; Perova NV; Kosmatova OV; Khadipash LA; Kiseleva NV; Oganov RG
    Kardiologiia; 2003; 43(3):13-9. PubMed ID: 12891253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of effects of lipid-lowering drugs on hemostasis.
    Altman R
    Am J Cardiol; 1998 Apr; 81(8A):73F-74F. PubMed ID: 9604916
    [No Abstract]   [Full Text] [Related]  

  • 18. Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safety.
    Ballantyne CM
    Am J Cardiol; 2003 Aug; 92(4B):3K-9K. PubMed ID: 12948870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unresolved issues in lipid-lowering treatment.
    Tziomalos K
    Panminerva Med; 2016 Jun; 58(2):191-5. PubMed ID: 27035401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.